Don’t let the high cost of brand specialty psoriasis biologics stand between you and the treatment you need. We help eligible patients access Taltz (ixekizumab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Taltz Prescription Assistance Program is a manufacturer-sponsored initiative that provides Taltz at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for patients with psoriasis or related inflammatory conditions who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, dermatology/rheumatology coordination, TB screening documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification — so you focus on your health, not paperwork.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$8,200.00 | Save ~$8,130/mo |
| CVS Pharmacy | ~$8,500.00 | Save ~$8,430/mo |
| Walmart | ~$7,500.00 | Save ~$7,430/mo |
| Costco | ~$7,200.00 | Save ~$7,130/mo |
| GoodRx Best Price | ~$7,000.00 | Save ~$6,930/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Taltz at no medication cost if approved. But the process involves detailed applications, dermatology or rheumatology coordination, TB screening documentation, specialty pharmacy logistics, and ongoing renewal management. Our $69.95/month service covers full advocacy: applications, doctor coordination, documentation, refill management, and annual re-enrollment.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Taltz:
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Taltz assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Taltz (ixekizumab) is a biologic medicine in the IL-17A inhibitor class used to treat moderate-to-severe plaque psoriasis (in adults and pediatric patients 6 and older), active psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is given as a subcutaneous injection — typically a loading phase of more frequent doses followed by every-four-week maintenance dosing.
How Cialis Works:
Plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis are all driven by overactive immune signaling involving the cytokine IL-17A. IL-17A drives the rapid skin-cell turnover that produces psoriasis plaques, the joint inflammation seen in psoriatic arthritis, and the spinal inflammation seen in ankylosing spondylitis.
Taltz is a monoclonal antibody that selectively binds to IL-17A and blocks it from interacting with its receptor. By neutralizing IL-17A, Taltz dampens the inflammatory cascade that drives these conditions — improving skin clearance in psoriasis, reducing joint pain and damage in psoriatic arthritis, and reducing spinal inflammation in axial spondyloarthritis.
Form and use:
Taltz is given by subcutaneous injection using a 80 mg/mL prefilled autoinjector or syringe. For plaque psoriasis (adults), the schedule is 160 mg at Week 0, then 80 mg at Weeks 2, 4, 6, 8, 10, and 12, followed by 80 mg every 4 weeks. Different schedules apply for psoriatic arthritis, axial spondyloarthritis, and pediatric psoriasis. The injection can be self-administered at home after training.
.
Generic availability:
There is no generic or biosimilar version of Taltz in the U.S. as of 2026. Other IL-17 inhibitors are FDA-approved (secukinumab/Cosentyx, brodalumab/Siliq, bimekizumab/Bimzelx); IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) are also options for psoriasis. TNF inhibitors (some now available as biosimilars) are also options for psoriatic arthritis and axial spondyloarthritis.
Warnings:
Important warnings include increased risk of serious infections, tuberculosis (TB) reactivation, hypersensitivity, and inflammatory bowel disease (new onset or exacerbation). TB screening before therapy is part of standard care. Tell your prescriber about any new abdominal pain or persistent diarrhea (could signal IBD).
The average retail price runs approximately $7,000–$8,500 per month. Annual costs commonly reach $80,000+ for ongoing therapy. Through AffordMyPrescriptions, qualifying patients receive Taltz at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Yes. Patients are typically screened for tuberculosis (latent and active) before starting Taltz, since IL-17 inhibitors can affect immune function. Your prescriber will also review your medical history, including any history of inflammatory bowel disease, recurrent infections, or vaccination needs.
Taltz is given by subcutaneous injection using a prefilled autoinjector or syringe. For plaque psoriasis in adults, the schedule is 160 mg at Week 0, then 80 mg at Weeks 2–12, followed by 80 mg every 4 weeks for maintenance. Different schedules apply for psoriatic arthritis, axial spondyloarthritis, and pediatric psoriasis. The injection can be self-administered at home after training.
Yes. Medicare Part D beneficiaries can typically qualify for Taltz Patient Assistance, especially if you face specialty-tier copays you cannot afford. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
If your initial application is denied, we explore alternative savings paths on your behalf — including independent foundations such as the PAN Foundation, HealthWell Foundation, or the National Psoriasis Foundation, the manufacturer’s copay savings program if you have commercial insurance, or asking your prescriber whether a different IL-17, IL-23, or TNF biologic would be appropriate. If we cannot find a path, you will not be charged our service fee.
If you are struggling with the high cost of Taltz, our team may be able to help you access assistance programs designed to make brand specialty psoriasis biologics affordable. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.